ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172.1 USD | +0.45% |
|
+3.34% | +11.07% |
| 06-20 | AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis | MT |
| 06-20 | US FDA proposes to remove switching study requirement for biosimilars | RE |
Presenter SpeechChris Shibutani (Analysts)Welcome, everybody. Glad that you can join us. My na...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
172.1
USD
Average target price
183.2
USD
Spread / Average Target
+6.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.07% | 304B | |
| +51.99% | 798B | |
| -5.72% | 356B | |
| +18.94% | 328B | |
| +16.96% | 244B | |
| +2.25% | 227B | |
| +11.15% | 216B | |
| +7.59% | 166B | |
| -3.65% | 157B | |
| -1.84% | 118B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10
